WHO Model List of Essential Medicines

19th List

(April 2015)

(Amended November 2015)

Status of this document

This is a reprint of the text on the WHO Medicines website

http://www.who.int/medicines/publications/essentialmedicines/en/



The published material is being distributed without warrant of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. DOCKET

Find authenticated court documents without watermarks at docketalarm.com.

19th edition

WHO Model List of Essential Medicines (April 2015)

Explanatory notes

The **core list** presents a list of minimum medicine needs for a basic health-care system, listing the most efficacious, safe and cost–effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment.

The **complementary list** presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings.

The **square box symbol** (□) is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources. Not all square boxes are applicable to medicine selection for children — see the second EMLc for details.

Therapeutic equivalence is indicated only on the basis of reviews of efficacy and safety and when consistent with WHO clinical guidelines. National lists should not use a similar symbol and should be specific in their final selection, which would depend on local availability and price.

The **a** symbol indicates that there is an age or weight restriction on use of the medicine; details for each medicine can be found in Table 1.1.

Where the **[c]** symbol is placed next to the complementary list it signifies that the medicine(s) require(s) specialist diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training for their use in children.

Where the **[c]** symbol is placed next to an individual medicine or strength of medicine it signifies that there is a specific indication for restricting its use to children.

The presence of an entry on the Essential Medicines List carries no assurance as to pharmaceutical quality. It is the responsibility of the relevant national or regional drug regulatory authority to ensure that each product is of appropriate pharmaceutical quality (including stability) and that, when relevant, different products are interchangeable.

For recommendations and advice concerning all aspects of the quality assurance of medicines see the WHO Medicines website http://www.who.int/medicines/areas/quality assurance.

Medicines and dosage forms are listed in alphabetical order within each section and there is no implication of preference for one form over another. Standard treatment guidelines should be consulted for information on appropriate dosage forms.

The main terms used for dosage forms in the Essential Medicines List can be found in Table 1.2.



Definitions of many of these terms and pharmaceutical quality requirements applicable to the different categories are published in the current edition of *The International Pharmacopoeia* http://www.who.int/medicines/publications/pharmacopoeia.



WHO Model List

1. ANAESTHETICS 1.1 General anaesthetics and oxygen 1.1.1 Inhalational medicines Inhalation. halothane isoflurane Inhalation. Inhalation. nitrous oxide Inhalation (medicinal gas). oxygen 1.1.2 Injectable medicines ketamine Injection: 50 mg (as hydrochloride)/ mL in 10- mL vial. Injection: 10 mg/ mL; 20 mg/ mL. propofol* * Thiopental may be used as an alternative depending on local availability and cost. 1.2 Local anaesthetics **Injection:** 0.25%; 0.5% (hydrochloride) in vial. □ bupivacaine Injection for spinal anaesthesia: 0.5% (hydrochloride) in 4- mL ampoule to be mixed with 7.5% glucose solution. **Injection:** 1%; 2% (hydrochloride) in vial. Injection for spinal anaesthesia: 5% (hydrochloride) in □ lidocaine 2- mL ampoule to be mixed with 7.5% glucose solution. **Topical forms:** 2% to 4% (hydrochloride). **Dental cartridge:** 2% (hydrochloride) + epinephrine 1:80 000. lidocaine + epinephrine (adrenaline) **Injection:** 1%; 2% (hydrochloride **or** sulfate) + epinephrine 1:200 000 in vial. Complementary List *Injection:* 30 mg (hydrochloride)/ mL in 1- mL ampoule. ephedrine (For use in spinal anaesthesia during delivery, to prevent hypotension). 1.3 Preoperative medication and sedation for short-term procedures atropine **Injection:** 1 mg (sulfate) in 1- mL ampoule. Injection: 1 mg/ mL. □ midazolam Oral liquid: 2 mg/ mL [c]. Tablet: 7.5 mg; 15 mg. morphine **Injection:** 10 mg (sulfate **or** hydrochloride) in 1- mL ampoule.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

